Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada
Abstract Background: With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its…
Abstract Background: With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its…
Abstract Cannabidiol (CBD) has been used as a pharmacological treatment for psychiatric disorders in many studies, but few of good…
Abstract Background: US states have been adopting their own medical cannabis laws since 1996. There is substantial variability in the…
Abstract Neurodevelopmental and neuropsychiatric disorders (such as autism spectrum disorder) have broad health implications for children, with no definitive cure…
Abstract In Fort McMurray, Alberta, Canada, the wildfire of May 2016 forced the population of 88,000 to rapidly evacuate in…
Abstract Psychiatric disorders are frequently encountered in many neurological disorders, such as Alzheimer’s and Parkinson diseases along with epilepsy, migraine,…
Abstract Fibroblast growth factors (FGFs) act as key signalling molecules in brain development, maintenance, and repair. They influence the intricate…
Abstract Background and Purpose: Src homology 3‐domain growth factor receptor‐bound 2‐like endophilin interacting protein 1 (SGIP1) interacts with cannabinoid CB1…
Abstract Synthetic cannabinoids can cause acute adverse psychological effects, but the potential impact when exposure happens before birth is unknown.…
Abstract Background: Public and medical interest in cannabidiol (CBD) has been rising, and CBD is now available from various sources.…